Navrogen Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$542K
Investors
13
Min Invest
$5,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Navrogen Inc. is a Delaware corporation that first filed a Form D on October 23, 2018 and most recently amended it on June 28, 2024 in the Biotechnology industry group. The offering claims Rule 506(b). Navrogen Inc. reported $542,000 sold from 13 investors of a $1,000,000 total offering as of the Form D filed June 28, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $5,000. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 1837 University Cir., Science Center Room 218, Cheyney, PA 19319.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
1
latest Jun 27, 2024
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
3
dark, closed, lapsed
Latest event New filer · Jun 27, 2024
SEC.govInvestor
- 1 filing event with values and deltas, latest 2024-06-27, and alerts on the next one
- 3 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2024-06-28: 2 related persons added and 0 removed against the filing of 2024-06-27; 4 now listed. The names are in the Terminal feed.
Nicholas C. Nicolaides
Executive Officer, Director · Glen Mills, PA
CEO and Director will use the proceeds to expand operations and the research and development pipeline.
Luigi C. Grasso
Executive Officer, Director · Bryn Mawr, PA
CSO will be using the proceeds to expand operations and the research and development pipeline.
Leon O Moulder, Jr
Director · Cheyney, PA
Allan O Bedwick
Director · Cheyney, PA
Questions About Navrogen Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Navrogen Inc.?
Navrogen Inc. is a Delaware corporation that filed a Form D with the SEC on June 28, 2024 in the Biotechnology industry group. The filing claims Rule 506(b).
Is Navrogen Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Navrogen Inc. filed a Form D with the SEC on June 28, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $542,000 sold to 13 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Navrogen Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Navrogen Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Navrogen Inc. raised?
Navrogen Inc. reported $542,000 sold from 13 investors of a $1,000,000 total offering as of the Form D filed June 28, 2024.
Who can invest in Navrogen Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $5,000.
What is the minimum investment in Navrogen Inc.?
The Form D lists $5,000 as the minimum investment accepted from any outside investor as of June 28, 2024. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Navrogen Inc. and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Navrogen Inc.?
The Form D lists 4 related persons: Nicholas C. Nicolaides, executive officer, director (CEO and Director will use the proceeds to expand operations and the research and development pipeline); Luigi C. Grasso, executive officer, director (CSO will be using the proceeds to expand operations and the research and development pipeline); Leon O Moulder, Jr, director; Allan O Bedwick, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Navrogen Inc. located?
The issuer's address on its SEC filings is 1837 University Cir., Science Center Room 218, Cheyney, PA 19319. Its phone number of record is (610) 660-1931. It is organized under the laws of Delaware.
How long is the Navrogen Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 3 amendments are on record for this CIK.
What is Navrogen Inc.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.